Werewolf Q3: $41.9M Cash, Going Concern, Dec 17 Merger Vote
HOWL has more than doubled off its 52-week low of $0.27.
Summary
Werewolf closed Q3 with $41.9 million in cash but reiterated going-concern doubt, with its survival tied to the Ambros reverse merger and a December 17, 2026 stockholder vote.
Key Events · Earnings and Guidance · HOWL
-
Q3 Cash Position and Going Concern
Cash and cash equivalents reached $41.9 million at September 30, 2026, up from the $22 million cited in the prior quarterly baseline, yet the filing states substantial doubt about continuing as a going concern for at least twelve months.
-
Nine-Month Loss Narrows Sharply
The net loss was $19.7 million for the nine months ended September 30, 2026, versus $52.4 million a year earlier, helped by $21.0 million of collaboration revenue from the Jazz asset sale and deep cost cuts.
-
Term Loan Repaid in Full
Repayment of the K2HV term loan on May 6, 2026 cost $31.4 million and produced a $3.4 million loss on extinguishment; no interest expense was recorded in Q3 2026.
-
EMD Proceeds Held as Deferred Income
The EMD asset sale carries a $33.9 million transaction price ($28.0 million upfront, $0.9 million reimbursement, $5.0 million on technology transfer); $28.85 million received to date sits in deferred income and is expected to be recognized in Q4 2026 on acceptance.
Analysis · HOWL · Life Sciences
Cash stood at $41.9 million on September 30, up from the $22 million cited in the prior quarterly baseline, lifted by the $21.0 million Jazz payment and $28.9 million received from EMD; the K2HV term loan was also repaid in full for $31.4 million. Even so, management flags substantial doubt about the company's ability to continue as a going concern for at least twelve months, and survival hinges on closing the Ambros reverse merger on time. The Form S-4 was declared effective November 12 and the stockholder vote is set for December 17, 2026; should the deal fail, the board may pursue another transaction or a dissolution and liquidation. Meanwhile, the EMD sale's $33.9 million transaction price remains in deferred income pending acceptance, expected in Q4 2026.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HOWL was trading at $0.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.6M. The 52-week trading range was $0.27 to $1.20. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.